Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Hengrui Pharma reported Q1 2026 revenue of RMB 8.14 billion, up 12.98% year-over-year, with net profit growing 21.78% to RMB 2.28 billion. Innovative drugs drove growth, generating RMB 4.53 billion in revenue, a 25.75% increase, and accounting for 61.69% of total pharmaceutical sales.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- RMB 8.14 billion
- Revenue Yoy
- 12.98%
- Deal Value Usd
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Rd investment
- RMB 2.22 billion
- Net profit growth
- 21.78%
- Out licensing revenue
- RMB 787 million
- Rd revenue percentage
- 27.32%
- Innovative drugs revenue
- RMB 4.53 billion
- Innovative drugs revenue growth
- 25.75%
- Innovative drugs sales percentage
- 61.69%
- Net profit attributable to shareholders
- RMB 2.28 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.